Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 56.73 -3.32% -1.95
EGRX closed down 3.32 percent on Friday, September 20, 2019, on 3.7 times normal volume. It was able to find support at its 50 day moving average.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical EGRX trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
50 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Outside Day Range Expansion 0.00%
Stochastic Sell Signal Bearish -3.45%
180 Bullish Setup Bullish Swing Setup -3.45%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.45%
NR7 Range Contraction -3.45%
Overbought Stochastic Strength -3.45%

Older signals for EGRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Medicine Chemistry Pharmaceutical Lymphoma Organic Chemistry Chronic Lymphocytic Leukemia Lung Cancer Treatment Of Chronic Lymphocytic Leukemia Direct Thrombin Inhibitors Heparin Induced Thrombocytopenia Injectable Products Nitrogen Mustards Organochlorides
Is EGRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 70.13
52 Week Low 36.03
Average Volume 142,999
200-Day Moving Average 50.0939
50-Day Moving Average 56.264
20-Day Moving Average 57.04
10-Day Moving Average 58.265
Average True Range 2.3999
ADX 18.62
+DI 13.4665
-DI 13.1371
Chandelier Exit (Long, 3 ATRs ) 52.9803
Chandelier Exit (Short, 3 ATRs ) 60.8897
Upper Bollinger Band 60.0348
Lower Bollinger Band 54.0452
Percent B (%b) 0.45
BandWidth 10.500701
MACD Line 0.5448
MACD Signal Line 0.5445
MACD Histogram 0.0003
Fundamentals Value
Market Cap 860.53 Million
Num Shares 15.2 Million
EPS 5.96
Price-to-Earnings (P/E) Ratio 9.52
Price-to-Sales 3.34
Price-to-Book 4.96
PEG Ratio 0.95
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 62.22
Resistance 3 (R3) 62.55 61.06 61.31
Resistance 2 (R2) 61.06 59.66 60.89 61.00
Resistance 1 (R1) 58.89 58.79 58.15 58.56 60.69
Pivot Point 57.40 57.40 57.02 57.23 57.40
Support 1 (S1) 55.23 56.00 54.49 54.90 52.77
Support 2 (S2) 53.74 55.13 53.57 52.46
Support 3 (S3) 51.57 53.74 52.16
Support 4 (S4) 51.24